Claims
- 1. A method of treating or inhibiting menopausal or postmenopausal disorders in a perimenopausal, menopausal, or postmenopausal woman in need thereof, which comprises orally providing to said woman continuously and uninterruptedly over the treatment period, a combination of a daily dosage of between 0.05 mg and 0.45 mg conjugated estrogens and a daily dosage of between 0.005 mg and about 0.025 mg of trimegestone.
- 2. The method according to claim 1, wherein the conjugated estrogens is conjugated equine estrogens, USP.
- 3. The method according to claim 2, wherein the daily dosage of conjugated equine estrogens is between 0.2 mg and 0.45 mg and the daily dosage of trimegestone is between 0.01 mg and 0.025 mg.
- 4. The method according to claim 3, wherein the daily dosage of trimegestone is 0.02 mg.
- 5. The method according to claim 1, wherein the daily dosage of conjugated estrogens is 0.2 mg and the daily dosage of trimegestone is 0.02 mg.
- 6. The method according to claim 1, wherein the conjugated estrogens is synthetic conjugated estrogens, A.
- 7. A method of treating or inhibiting vasomotor symptoms in a perimenopausal, menopausal, or postmenopausal woman in need thereof, which comprises orally providing to said woman continuously and uninterruptedly over the treatment period, a combination of a combination of a daily dosage of between 0.05 mg and 0.45 mg conjugated estrogens and a daily dosage of between 0.005 mg and about 0.025 mg of trimegestone.
- 8. The method according to claim 7, wherein the conjugated estrogens is conjugated equine estrogens, USP.
- 9. The method according to claim 8, wherein the daily dosage of conjugated equine estrogens is between 0.2 mg and 0.45 mg and the daily dosage of trimegestone is between 0.01 mg and 0.025 mg.
- 10. The method according to claim 9, wherein the daily dosage of trimegestone is 0.02 mg.
- 11. The method according to claim 7, wherein the daily dosage of conjugated estrogens is 0.2 mg and the daily dosage of trimegestone is 0.02 mg.
- 12. The method according to claim 7, wherein the conjugated estrogens is synthetic conjugated estrogens, A.
- 13. A method of inhibiting or retarding bone demineralization or treating or inhibiting osteoporosis in a perimenopausal, menopausal, or postmenopausal woman in need thereof, which comprises orally providing to said woman continuously and uninterruptedly over the treatment period, a combination of a daily dosage of between 0.05 mg and 0.45 mg conjugated estrogens and a daily dosage of between 0.005 mg and about 0.025 mg of trimegestone.
- 14. The method according to claim 13, wherein the conjugated estrogens is conjugated equine estrogens, USP.
- 15. The method according to claim 14, wherein the daily dosage of conjugated equine estrogens is between 0.2 mg and 0.45 mg and the daily dosage of trimegestone is between 0.01 mg and 0.025 mg.
- 16. The method according to claim 15, wherein the daily dosage of trimegestone is 0.02 mg.
- 17. The method according to claim 13, wherein the daily dosage of conjugated estrogens is 0.2 mg and the daily dosage of trimegestone is 0.02 mg.
- 18. The method according to claim 13, wherein the conjugated estrogens is synthetic conjugated estrogens, A.
- 19. A method of treating or inhibiting vaginal or vulvar atrophy; atrophic vaginitis; vaginal dryness; pruritus; dyspareunia; dysuria; frequent urination; urinary incontinence; urinary tract infections in a perimenopausal, menopausal, or postmenopausal woman in need thereof, which comprises orally providing to said woman continuously and uninterruptedly over the treatment period, a combination of a daily dosage of between 0.05 mg and 0.45 mg conjugated estrogens and a daily dosage of between 0.005 mg and about 0.025 mg of trimegestone.
- 20. The method according to claim 19, wherein the conjugated estrogens is conjugated equine estrogens, USP.
- 21. The method according to claim 20, wherein the daily dosage of conjugated equine estrogens is between 0.2 mg and 0.45 mg and the daily dosage of trimegestone is between 0.01 mg and 0.025 mg.
- 22. The method according to claim 21, wherein the daily dosage of trimegestone is 0.02 mg.
- 23. The method according to claim 19, wherein the daily dosage of conjugated estrogens is 0.2 mg and the daily dosage of trimegestone is 0.02 mg.
- 24. The method according to claim 19, wherein the conjugated estrogens is synthetic conjugated estrogens, A.
- 25. A method of lowering cholesterol, Lp(a), or LDL levels; inhibiting or treating hypercholesteremia; hyperlipidemia; cardiovascular disease; atherosclerosis; peripheral vascular disease; restenosis, vasospasm; or inhibiting vascular wall damage from cellular events leading toward immune mediated vascular damage, in a perimenopausal, menopausal, or postmenopausal woman in need thereof, which comprises orally providing to said woman continuously and uninterruptedly over the treatment period, a combination of a combination of a daily dosage of between 0.05 mg and 0.45 mg conjugated estrogens and a daily dosage of between 0.005 mg and about 0.025 mg of trimegestone.
- 26. The method according to claim 25, wherein the conjugated estrogens is conjugated equine estrogens, USP.
- 27. The method according to claim 26, wherein the daily dosage of conjugated equine estrogens is between 0.2 mg and 0.45 mg and the daily dosage of trimegestone is between 0.01 mg and 0.025 mg.
- 28. The method according to claim 27, wherein the daily dosage of trimegestone is 0.02 mg.
- 29. The method according to claim 25, wherein the daily dosage of conjugated estrogens is 0.2 mg and the daily dosage of trimegestone is 0.02 mg.
- 30. The method according to claim 25, wherein the conjugated estrogens is synthetic conjugated estrogens, A.
- 31. A method of treating or inhibiting free radical involvement in the development of cancers, central nervous system disorders, Alzheimer's disease, bone disease, aging, inflammatory disorders, peripheral vascular disease, rheumatoid arthritis, autoimmune diseases, respiratory distress, emphysema, prevention of reperfusion injury, viral hepatitis, chronic active hepatitis, tuberculosis, psoriasis, systemic lupus erythematosus, amyotrophic lateral sclerosis, aging effects, adult respiratory distress syndrome, central nervous system trauma and stroke, or injury during reperfusion procedures in a perimenopausal, menopausal, or postmenopausal woman in need thereof, which comprises orally providing to said woman continuously and uninterruptedly over the treatment period, a combination of a daily dosage of between 0.05 mg and 0.45 mg conjugated estrogens and a daily dosage of between 0.005 mg and about 0.025 mg of trimegestone.
- 32. The method according to claim 31, wherein the conjugated estrogens is conjugated equine estrogens, USP.
- 33. The method according to claim 32, wherein the daily dosage of conjugated equine estrogens is between 0.2 mg and 0.45 mg and the daily dosage of trimegestone is between 0.01 mg and 0.025 mg.
- 34. The method according to claim 33, wherein the daily dosage of trimegestone is 0.02 mg.
- 35. The method according to claim 31, wherein the daily dosage of conjugated estrogens is 0.2 mg and the daily dosage of trimegestone is 0.02 mg.
- 36. The method according to claim 31, wherein the conjugated estrogens is synthetic conjugated estrogens, A.
- 37. A method of treating or inhibiting dementias, neurodegenerative disorders, and Alzheimer's disease; providing neuroprotection or cognition enhancement in a perimenopausal, menopausal, or postmenopausal woman in need thereof, which comprises orally providing to said woman continuously and uninterruptedly over the treatment period, a combination of a daily dosage of between 0.05 mg and 0.45 mg conjugated estrogens and a daily dosage of between 0.005 mg and about 0.025 mg of trimegestone.
- 38. The method according to claim 37, wherein the conjugated estrogens is conjugated equine estrogens, USP.
- 39. The method according to claim 38, wherein the daily dosage of conjugated equine estrogens is between 0.2 mg and 0.45 mg and the daily dosage of trimegestone is between 0.01 mg and 0.025 mg.
- 40. The method according to claim 39, wherein the daily dosage of trimegestone is 0.02 mg.
- 41. The method according to claim 37, wherein the daily dosage of conjugated estrogens is 0.2 mg and the daily dosage of trimegestone is 0.02 mg.
- 42. The method according to claim 37, wherein the conjugated estrogens is synthetic conjugated estrogens, A.
- 43. A pharmaceutical composition for use in treating menopausal or postmenopausal disorders, which comprises a dosage of between 0.05 mg and 0.45 mg conjugated estrogens and a dosage of between 0.005 mg and about 0.025 mg of trimegestone, and a pharmaceutical carrier.
- 44. The composition according to claim 43, wherein the conjugated estrogens is conjugated equine estrogens, USP.
- 45. The composition according to claim 43, wherein the dosage of conjugated estrogens is between 0.2 mg and 0.45 mg and the dosage of trimegestone is between 0.01 mg and 0.025 mg.
- 46. The composition according to claim 45, wherein the dosage of trimegestone is 0.02 mg.
- 47. The composition according to claim 43, wherein the dosage of conjugated estrogens is 0.2 mg and the dosage of trimegestone is 0.02 mg.
- 48. The composition according to claim 43, wherein the conjugated estrogens is synthetic conjugated estrogens, A.
- 49. A pharmaceutical dosage unit which comprises which comprises conjugated estrogens, a dosage of between 0.05 mg and 0.45 mg conjugated estrogens and a dosage of between 0.005 mg and about 0.025 mg of trimegestone, and a pharmaceutical carrier.
- 50. The dosage unit according to claim 49, wherein the conjugated estrogens is conjugated equine estrogens, USP.
- 51. The dosage unit according to claim 50, wherein the trimegestone acetate is micronized.
- 52. The dosage unit according to claim 49, wherein the dosage of conjugated estrogens is between 0.2 mg and 0.45 mg and the dosage of trimegestone is between 0.01 mg and 0.025 mg.
- 53. The dosage unit according to claim 52, wherein the dosage of trimegestone is 0.02 mg.
- 54. The dosage unit according to claim 49, wherein the dosage of conjugated estrogens is 0.2 mg and the dosage of trimegestone is 0.02 mg.
- 55. The dosage unit according to claim 49, wherein the conjugated estrogens is synthetic conjugated estrogens, A.
- 56. A method of minimizing or reducing levels of breast pain in a woman receiving hormone replacement therapy, which comprises orally providing to said woman continuously and uninterruptedly over the treatment period, a combination of a daily dosage of between 0.05 mg and 0.45 mg conjugated estrogens and a daily dosage of between 0.005 mg and about 0.025 mg of trimegestone.
- 57. The method according to claim 56, wherein the conjugated estrogens is conjugated equine estrogens, USP.
- 58. The method according to claim 57, wherein the daily dosage of conjugated equine estrogens is between 0.2 mg and 0.45 mg and the daily dosage of trimegestone is between 0.01 mg and 0.025 mg.
- 59. The method according to claim 58, wherein the daily dosage of trimegestone is 0.02 mg.
- 60. The method according to claim 56, wherein the daily dosage of conjugated estrogens is 0.2 mg and the daily dosage of trimegestone is 0.02 mg.
- 61. The method according to claim 56, wherein the conjugated estrogens is synthetic conjugated estrogens, A.
- 62. A method of minimizing spotting or breakthrough bleeding; or achieving amenorrhea in a woman receiving hormone replacement therapy, which comprises orally providing to said woman continuously and uninterruptedly over the treatment period, a combination of a daily dosage of between 0.05 mg and 0.45 mg conjugated estrogens and a daily dosage of between 0.005 mg and about 0.025 mg of trimegestone.
- 63. The method according to claim 62, wherein the conjugated estrogens is conjugated equine estrogens, USP.
- 64. The method according to claim 63, wherein the daily dosage of conjugated equine estrogens is between 0.2 mg and 0.45 mg and the daily dosage of trimegestone is between 0.01 mg and 0.025 mg.
- 65. The method according to claim 64, wherein the daily dosage of trimegestone is 0.02 mg.
- 66. The method according to claim 62, wherein the daily dosage of conjugated estrogens is 0.2 mg and the daily dosage of trimegestone is 0.02 mg.
- 67. The method according to claim 62, wherein the conjugated estrogens is synthetic conjugated estrogens, A.
- 68. A method of increasing bone mineral density in a perimenopausal, menopausal, or postmenopausal woman in need thereof, which comprises orally providing to said woman continuously and uninterruptedly over the treatment period, a combination of a daily dosage of between 0.05 mg and 0.45 mg conjugated estrogens and a daily dosage of between 0.005 mg and about 0.025 mg of trimegestone.
- 69. The method according to claim 68, wherein the conjugated estrogens is conjugated equine estrogens, USP.
- 70. The method according to claim 69, wherein the daily dosage of conjugated equine estrogens is between 0.2 mg and 0.45 mg and the daily dosage of trimegestone is between 0.01 mg and 0.025 mg.
- 71. The method according to claim 70, wherein the daily dosage of trimegestone is 0.02 mg.
- 72. The method according to claim 68, wherein the daily dosage of conjugated estrogens is 0.2 mg and the daily dosage of trimegestone is 0.02 mg.
- 73. The method according to claim 68, wherein the conjugated estrogens is synthetic conjugated estrogens, A.
Parent Case Info
[0001] This application claims priority from copending provisional application Serial No. 60/369,682, filed Apr. 3, 2002, the entire disclosure of which is hereby incorporated by reference.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60369682 |
Apr 2002 |
US |